Xeris Pharmaceuticals, Inc. (XERS): Price and Financial Metrics


Xeris Pharmaceuticals, Inc. (XERS): $2.53

-0.09 (-3.44%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

XERS POWR Grades


  • Value is the dimension where XERS ranks best; there it ranks ahead of 62.45% of US stocks.
  • XERS's strongest trending metric is Value; it's been moving up over the last 48 weeks.
  • XERS's current lowest rank is in the Stability metric (where it is better than 0.79% of US stocks).

XERS Stock Summary

  • XERS's went public 3.26 years ago, making it older than merely 9.5% of listed US stocks we're tracking.
  • As for revenue growth, note that XERS's revenue has grown 464.94% over the past 12 months; that beats the revenue growth of 98.28% of US companies in our set.
  • In terms of volatility of its share price, XERS is more volatile than 90.12% of stocks we're observing.
  • Stocks that are quantitatively similar to XERS, based on their financial statements, market capitalization, and price volatility, are CYRX, PRTK, EVFM, RDHL, and CNTG.
  • Visit XERS's SEC page to see the company's official filings. To visit the company's web site, go to www.xerispharma.com.

XERS Valuation Summary

  • In comparison to the median Healthcare stock, XERS's price/earnings ratio is 106.03% lower, now standing at -2.2.
  • XERS's price/earnings ratio has moved up 12.3 over the prior 39 months.
  • Over the past 39 months, XERS's price/sales ratio has gone down 242.

Below are key valuation metrics over time for XERS.

Stock Date P/S P/B P/E EV/EBIT
XERS 2021-08-31 5.4 9.2 -2.2 -2.8
XERS 2021-08-30 5.4 9.2 -2.2 -2.8
XERS 2021-08-27 5.6 9.5 -2.2 -2.9
XERS 2021-08-26 5.6 9.5 -2.3 -2.9
XERS 2021-08-25 5.4 9.2 -2.2 -2.8
XERS 2021-08-24 5.3 8.9 -2.1 -2.7

XERS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • XERS has a Quality Grade of D, ranking ahead of 12.22% of graded US stocks.
  • XERS's asset turnover comes in at 0.208 -- ranking 196th of 677 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows XERS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.208 0.661 -0.415
2021-03-31 0.162 0.651 -0.388
2020-12-31 0.134 0.544 -0.482
2020-09-30 0.107 0.504 -0.626
2020-06-30 0.046 0.218 -0.894
2020-03-31 0.035 0.204 -1.151

XERS Price Target

For more insight on analysts targets of XERS, see our XERS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $10.00 Average Broker Recommendation 1.33 (Strong Buy)

XERS Stock Price Chart Interactive Chart >

Price chart for XERS

XERS Price/Volume Stats

Current price $2.53 52-week high $7.94
Prev. close $2.62 52-week low $2.16
Day low $2.49 Volume 446,664
Day high $2.67 Avg. volume 3,117,537
50-day MA $2.71 Dividend yield N/A
200-day MA $4.10 Market Cap 168.24M

Xeris Pharmaceuticals, Inc. (XERS) Company Bio


Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps. The company’s lead product candidate is glucagon rescue pen, which has completed Phase III clinical trials for the treatment of severe hypoglycemia, a potentially life-threatening condition in people with diabetes. Its product candidates also comprise self-administered glucagon that is in Phase IIa clinical trials for the treatment of post-bariatric hypoglycemia; continuous glucagon, which is in Phase II clinical trials for the treatment of congenital hyperinsulinism; continuous glucagon that is in Phase IIa clinical trials for the treatment of hypoglycemia-associated autonomic failure; self-administered glucagon, which is in Phase IIa clinical trials for the treatment of exercise-induced hypoglycemia; and ready-to-use glucagon that is in Phase II clinical trials for use in a bi-hormonal artificial pancreas closed-loop systems. The company’s preclinical programs include ready-to-use diazepam, a ready-to-use diazepam formulation for the treatment of ARS in patients with epilepsy; and pram-insulin, a ready-to-use fixed dose combination of insulin and pramlintide. It serves patients, caregivers, and health practitioners. The company was founded in 2005 and is based in Chicago, Illinois.


XERS Latest News Stream


Event/Time News Detail
Loading, please wait...

XERS Latest Social Stream


Loading social stream, please wait...

View Full XERS Social Stream

Latest XERS News From Around the Web

Below are the latest news stories about Xeris Pharmaceuticals Inc that investors may wish to consider to help them evaluate XERS as an investment opportunity.

How Much Of Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) Do Institutions Own?

Every investor in Xeris Pharmaceuticals, Inc. ( NASDAQ:XERS ) should be aware of the most powerful shareholder groups...

Yahoo | September 22, 2021

Xeris Pharmaceuticals to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

CHICAGO, September 17, 2021--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable drug formulations, today announced that Paul R. Edick, Chairman and Chief Executive Officer of Xeris Pharmaceuticals, will present an overview of the Company at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Wednesday, September 22, 2021, at 8:15 a.m. Eastern Time. The presentation can b

Yahoo | September 17, 2021

The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 14) Alcon Inc. (NYSE: ALC) aTyr Pharma, Inc. (NASDAQ: LIFE) (reacted to positive analyst action following a positive clinical readout announced Monday) Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) BELLUS Health Inc. (NASDAQ: BLU) Itamar Medical Ltd. (NASDAQ: ITMR) IVERIC bio, Inc. (NASDAQ: ISEE) Kezar Life Sciences, Inc. (NASDAQ: KZR) PPD, Inc. (NASDAQ: P

Yahoo | September 15, 2021

Xeris Pharmaceuticals Stockholders Approve Acquisition of Strongbridge Biopharma

CHICAGO, September 14, 2021--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) ("Xeris") today announced that its stockholders have voted to approve the previously announced proposed acquisition of Strongbridge Biopharma plc (NASDAQ: SBBP) ("Strongbridge") by Xeris.

Yahoo | September 14, 2021

Strongbridge Biopharma plc Announces Shareholder Approval of Proposed Acquisition by Xeris Pharmaceuticals, Inc.

DUBLIN, Ireland and TREVOSE, Pa., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ: SBBP) (the “Company” or “Strongbridge”) today announced that its shareholders have voted to approve the previously announced proposed acquisition of Strongbridge by Xeris Pharmaceuticals, Inc. (NASDAQ: XERS) (“Xeris”). As described below, at least 99 percent of the votes cast at both a special court-ordered meeting of shareholders (the “Court Meeting”) and at an extraordinary general meeting

Yahoo | September 8, 2021

Read More 'XERS' Stories Here

XERS Price Returns

1-mo -10.60%
3-mo -37.84%
6-mo -43.90%
1-year -56.00%
3-year -85.61%
5-year N/A
YTD -48.58%
2020 -30.21%
2019 -58.53%
2018 N/A
2017 N/A
2016 N/A

Continue Researching XERS

Want to see what other sources are saying about Xeris Pharmaceuticals Inc's financials and stock price? Try the links below:

Xeris Pharmaceuticals Inc (XERS) Stock Price | Nasdaq
Xeris Pharmaceuticals Inc (XERS) Stock Quote, History and News - Yahoo Finance
Xeris Pharmaceuticals Inc (XERS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8047 seconds.